Laboratory of Human Metabolism in Critical States, Negovsky Research Institute of General Reanimatology, Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Petrovka str., 25-2, 107031 Moscow, Russia.
A.N. Frumkin Institute of Physical Chemistry and Electrochemistry, Russian Academy of Sciences, GSP-1, Leninsky Prospect, 31, 119071 Moscow, Russia.
Molecules. 2020 Jul 17;25(14):3258. doi: 10.3390/molecules25143258.
Indole-containing acids-tryptophan metabolites-found in serum and cerebrospinal fluid (CSF) samples of patients with diseases of the central nervous system (CNS) were determined with the use of microextraction by packed sorbent (MEPS) followed by silylation and gas chromatography-mass spectrometry (GC-MS) analysis. MEPS with the following silylation led to the reproducible formation of derivatives with an unsubstituted hydrogen ion in the indole ring, the chromatographic peaks of which are symmetric and can be used for GC-MS analysis without additional derivatization. The recoveries of analytes at the limit of quantitation (LOQ) levels were 40-80% for pooled CSF and 40-60% for serum. The limit of detection (LOD) and LOQ values were 0.2-0.4 and 0.4-0.5 µM, respectively, for both CSF and serum. The precision (the reproducibility, RSD) value of less than 20% and the accuracy (the relative error, RE) value of less than ±20% at the LOQ concentrations meet the Food and Drug Administration (FDA) recommendations. Linear correlations for all analytes were determined over a potentially clinically significant range of concentrations (0.4-10 µM for serum, ≥ 0.9942, and 0.4-7 µM for CSF, ≥ 0.9949). Moreover, MEPS significantly reduced the matrix effect of serum compared to liquid-liquid extraction (LLE), which was revealed in the example of reducing the amount of cholesterol and its relative compounds.
采用微萃取填充吸附剂(MEPS)结合硅烷化衍生和气相色谱-质谱(GC-MS)分析方法,对中枢神经系统(CNS)疾病患者血清和脑脊液(CSF)样本中的含吲哚酸-色氨酸代谢物进行了测定。采用 MEPS 结合硅烷化衍生,可重现地生成吲哚环中未取代氢离子的衍生物,其色谱峰对称,无需进一步衍生化即可用于 GC-MS 分析。在定量限(LOQ)水平下,分析物的回收率在 CSF 中的为 40-80%,在血清中的为 40-60%。CSF 和血清的检测限(LOD)和定量限(LOQ)值分别为 0.2-0.4 和 0.4-0.5 µM。LOQ 浓度下的精密度(重现性,RSD)值小于 20%,准确度(相对误差,RE)值小于±20%,符合美国食品和药物管理局(FDA)的建议。所有分析物在潜在临床相关浓度范围内(血清为 0.4-10 µM,≥0.9942;CSF 为 0.4-7 µM,≥0.9949)均具有线性相关性。此外,与液液萃取(LLE)相比,MEPS 显著降低了血清的基质效应,这在降低胆固醇及其相关化合物的量方面得到了体现。